China
Africa
Explore chapters and articles related to this topic
Infantile Atopic Dermatitis
Published in Donald Rudikoff, Steven R. Cohen, Noah Scheinfeld, Atopic Dermatitis and Eczematous Disorders, 2014
Sadaf H. Hussain, James R. Treat, Albert C. Yan
Eczema vaccinatum is a rare, life-threatening reaction occurring in patients with atopic dermatitis who are exposed to the smallpox vaccine virus. Although the prevalence of this condition has decreased since cessation of mandatory vaccinia immunizations, children of military personnel and others receiving the vaccine are still at risk because immunized individuals can shed live virus and inoculate contacts. As a result of the severity of the reaction, immunization of patients with atopic dermatitis or their close contacts is generally contraindicated unless smallpox represents an immediate risk. In the event of eczema vaccinatum, affected patients should be treated promptly with intramuscular vaccinia immune globulin (Centers for Disease Control and Prevention or CDC 2008).
Mpox: epidemiology, clinical manifestations and recent developments in treatment and prevention
Published in Expert Review of Anti-infective Therapy, 2023
Nikil Selvaraj, Shreya Shyam, Puvin Dhurairaj, Kaviarasan Thiruselvan, Akil Thiruselvan, Yochana Kancherla, Pritika Kandamaran
Cidofovir was given FDA approval in 1996, for the treatment of individuals with retinitis due to cytomegalovirus (CMV) in those suffering from acquired immunodeficiency syndrome, Adenoviruses, OPXV, herpes viruses, and viruses from other families are all susceptible to the antiviral effects of cidofovir [20]. Regarding its usage in OPXV infections, cidofovir was included in the treatment plan for a 28-month-old child with refractory atopic dermatitis who developed severe eczema vaccinatum after coming into contact with his father, who had been immunized against smallpox. The child lived without experiencing any long-term effects [20].